Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review

Table 4 Summary of results of included articles in the total group, as well as different disease groups n (%)

Total number of patients	CD	UC	IBDu	Daily dose (mg)1	Treatment years2	Benefit3	No benefit	Discontinuation
353	225 (64)	119 (34)	9 (2)	20	268	228 (65)	53 (15)	72 (20)
				[10-80]
								Discontinuation	Response unknown4
Crohn’s disease (n = 225)					141	118 (52)	25 (11)	40 (18)	42 (19)
Ulcerative colitis (n = 119)					122	73 (62)	16 (13)	11 (9)	19 (16)

¹Median start dose of thioguanine was 20 mg/d. This was adjusted based on symptoms and metabolite levels to doses of 10-80/d;

²Treatment years are calculated based on sample size and median follow-up;

³Defined as a clinically relevant decrease in disease activity scores by global physician assessment or when corticosteroids could be tapered or discontinued;

⁴When results are not subdivided in disease entities (i.e., total results are given, but not for CD/UC). CD: Crohn’s disease; UC: Ulcerative colitis; IBDu: Inflammatory bowel disease unclassified.